Peripheral Nervous System Neoplasms: Clinical Trials

171 completed, 55 recruiting, 40 unknown, 36 terminated. 135 Phase 2, 108 Phase 1, 55 Not applicable, 21 Phase 3, 8 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	135	Completed 65, Terminated 21, Recruiting 18, Active not recruiting 12, Unknown 8, Not yet recruiting 6, Withdrawn 4, Enrolling by invitation 1
Phase 1	108	Completed 60, Recruiting 16, Terminated 13, Active not recruiting 9, Unknown 3, Enrolling by invitation 2, Not yet recruiting 2, Withdrawn 2, Suspended 1
Not applicable	55	Completed 20, Recruiting 12, Unknown 9, Withdrawn 6, Terminated 4, Active not recruiting 2, Enrolling by invitation 1, Not yet recruiting 1
Phase 3	21	Completed 12, Terminated 3, Active not recruiting 2, Recruiting 2, Unknown 1, Withdrawn 1
Early Phase 1	8	Completed 5, Recruiting 1, Terminated 1, Withdrawn 1
Phase 4	3	Withdrawn 2, Active not recruiting 1

Follow Peripheral Nervous System Neoplasms: new trials by email Literature Review of Peripheral Nervous System Neoplasms trials Research Report on Peripheral Nervous System Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Role of ChatGPT in Vestibular Schwannoma Management Use of chatGPT for 1 week - Vestibular Schwannoma	Not applicable	Withdrawn	University of Southern California		2027-01-01	2026-01-13
Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor)	Phase 2	Not yet recruiting	Girish Dhall, MD	25	2027-01-01	2026-10-28
Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2	Phase 2	Not yet recruiting	Beijing Tiantan Hospital	20	2026-12-01	2026-10-28
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Selumetinib + ZEN-3694 ± Durvalumab - MPNST, NF1	Phase 2	Recruiting	University of Alabama at Birmingham	41	2026-08-04	2026-08-24
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST	Phase 1 / Phase 2	Recruiting	Ankit Mangla, MD	17	2026-08-01	2026-08-11
Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2	Phase 1 / Phase 2	Not yet recruiting	Beijing Tiantan Hospital	30	2026-07-31	2026-07-16
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma	Phase 2	Not yet recruiting	Beijing Tiantan Hospital	200	2026-07-18	2026-07-20
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures Panitumumab-IRDye800 - Meningioma, Glioblastoma	Early Phase 1	Recruiting	Eben Rosenthal	30	2026-07-07	2026-10-16
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT) - Bladder Cancer, Nerve Sheath Tumor	Phase 1	Recruiting	Robert Flavell, MD, PhD	40	2026-06-15	2026-10-01
Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas Cabozantinib Oral Tablet, Selumetinib Oral Capsule - Neurofibromatosis 1, Plexiform Neurofibroma	Phase 1	Recruiting	Girish Dhall, MD	30	2026-06-09	2026-10-02
Measuring Vestibular Organ Function With Weak Alternating Current Stimulation Active transcranial electrical vestibular stimulation (Active EVS), Sham transcranial electrical vestibular stimulation (Sham EVS), Control measurement - Vestibular Disorder, Vestibular Schwannoma	Not applicable	Enrolling by invitation	Aalto University	30	2026-06-08	2026-07-01
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1)	Phase 1 / Phase 2	Recruiting	AeRang Kim	45	2026-06-01	2026-07-27
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins Neurofibromas, MPNST		Recruiting	M.D. Anderson Cancer Center	60	2026-04-02	2026-09-18
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas TQ-B3234 capsules, TQ-B3234 placebo - Plexiform Neurofibroma	Phase 3	Recruiting	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	177	2026-03-31	2026-05-27
Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery Oliceridine, Sufentanil - PONV, Cerebellopontine Angle Tumor	Not applicable	Recruiting	Xuanwu Hospital, Beijing	174	2026-03-25	2026-05-22
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy Vestibular Schwannoma		Enrolling by invitation	Akouos, Inc.	100	2026-03-02	2026-07-16
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1) AlgometRx Nociometer(R) - Neurofibromatosis Type 1	Not applicable	Recruiting	National Cancer Institute (NCI)	70	2026-02-18	2026-10-16
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma	Phase 1 / Phase 2	Recruiting	University of Florida	27	2026-02-11	2026-06-30
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 Imlygic - NF1, Neurofibromatosis	Phase 1	Recruiting	Johns Hopkins University	10	2026-02-01	2026-05-08
A Study of DEG6498 in Participants With Solid Tumors DEG6498 - Malignant Neoplasms	Phase 1	Recruiting	Degron Therapeutics Co.	100	2025-11-13	2026-06-30

Showing 20 of 363. Sign in to see all of them.

Narrower conditions

Neuroma, Acoustic (98)  ·  Neurofibrosarcoma (97)  ·  Sarcoma (84)  ·  Optic Nerve Glioma (82)  ·  Astrocytoma (79)  ·  Neurofibromatosis 1 (70)  ·  Neurofibroma, Plexiform (62)  ·  Medulloblastoma (58)  ·  Oligodendroglioma (58)  ·  Familial ependymoma (55)  ·  Central Nervous System Neoplasms (51)  ·  Sarcoma, Synovial (48)  ·  Leiomyosarcoma (46)  ·  Choroid Plexus Neoplasms (43)  ·  Histiocytoma, Malignant Fibrous (42)

Broader conditions

Nervous System Neoplasms (363)  ·  Nervous System Diseases (362)  ·  Neoplasms by Histologic Type (358)  ·  Neoplasms, Nerve Tissue (357)  ·  Neoplasms (351)  ·  Nerve Sheath Neoplasms (270)  ·  Neoplasms by Site (225)  ·  Neuroectodermal Tumors (208)  ·  Neoplasms, Germ Cell and Embryonal (204)  ·  Neuromuscular Diseases (191)  ·  Peripheral Nervous System Diseases (189)  ·  Cranial Nerve Diseases (183)  ·  Cranial Nerve Neoplasms (183)  ·  Neurofibroma (173)

Interventions

Doxorubicin (19)  ·  AZD 6244 (17)  ·  Ifosfamide (15)  ·  Radiotherapy (14)  ·  Temozolomide (14)  ·  Carboplatin (13)  ·  Filgrastim (13)  ·  Etoposide (9)  ·  Radiosurgery (8)  ·  Bevacizumab (7)  ·  Everolimus (6)  ·  Imatinib Mesylate (6)  ·  Magnetic Resonance Spectroscopy (6)  ·  Vincristine (6)  ·  pazopanib (6)

Sponsors

National Cancer Institute (NCI) (59)  ·  Children's Oncology Group (14)  ·  European Organisation for Research and Treatment of Cancer - EORTC (13)  ·  Memorial Sloan Kettering Cancer Center (8)  ·  Pediatric Brain Tumor Consortium (8)  ·  AstraZeneca (7)  ·  Beijing Tiantan Hospital (5)  ·  Novartis Pharmaceuticals (5)  ·  Sarcoma Alliance for Research through Collaboration (5)  ·  University of Alabama at Birmingham (5)  ·  Washington University School of Medicine (5)  ·  Johns Hopkins University (4)  ·  Massachusetts Eye and Ear Infirmary (4)  ·  Mayo Clinic (4)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4)

Countries

United States (231)  ·  Canada (31)  ·  France (29)  ·  China (26)  ·  United Kingdom (20)  ·  Germany (17)  ·  Australia (14)  ·  Netherlands (14)  ·  Belgium (13)  ·  Switzerland (11)  ·  Denmark (10)  ·  Austria (9)  ·  Spain (9)  ·  Italy (8)  ·  Puerto Rico (8)

Top investigators

Brigitte C Widemann, M.D. (11)  ·  AeRang Kim, MD, PhD (3)  ·  Brigitte C. Widemann, MD (3)  ·  Elizabeth Fox, MD (3)  ·  Henry S. Friedman, MD (3)  ·  Staci M Peron, Ph.D. (3)  ·  Aaron Tward, MD (2)  ·  Anhua Wu, MD (2)  ·  Brigitte Widemann, MD (2)  ·  Chie-Schin Shih, MD (2)  ·  Douglas R Stewart, M.D. (2)  ·  Eric Legius, MD PhD (2)  ·  Fu Zhao (2)

Results publications

PMID 17917842, PMID 19574236, PMID 19645909, PMID 22027076, PMID 31401903, PMID 35007270, PMID 10449559, PMID 11587600, PMID 11705489, PMID 11710496, PMID 11981398, PMID 12528778, PMID 12925338, PMID 12943357, PMID 12957454, PMID 14724495, PMID 15010069, PMID 15177491, PMID 15354006, PMID 15519876, PMID 15592836, PMID 15659504, PMID 15814645, PMID 16234526, PMID 16408203, PMID 16528479, PMID 16533779, PMID 16914576, PMID 17095209, PMID 17336054, PMID 17438254, PMID 17562049, PMID 17610262, PMID 17634493, PMID 17634494, PMID 17941066, PMID 18048828, PMID 18281544, PMID 18281546, PMID 18607963, PMID 18769654, PMID 18989154, PMID 19065567, PMID 19075272, PMID 19088049, PMID 19430790, PMID 19451429, PMID 19451433, PMID 19645932, PMID 20044751

NIH funding

U01CA081457 (9), U01CA097452 (8), U10CA098543 (8), P30CA008748 (4), U10CA180886 (3), N01CM62206 (2), P30CA012197 (2), P30CA033572 (2), U01CA069856 (2), U10CA081920 (2), U10CA180821 (2), 2005 (1), 2009 (1), 2017 (1), 2018 (1)